Navigation Links
Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
Date:6/22/2011

BANGALORE, India, June 23, 2011 /PRNewswire/ --


 

Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area.

The collaboration, initiated two years ago in the Neuroscience therapeutic area, has now expanded to Cardiovascular and Metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca, by Jubilant. AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development,Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: "We are pleased that we have delivered outcomes and early success to the portfolio efforts at AstraZeneca.  This is the result of excellent collaboration between scientists at Jubilant and AstraZeneca.

"Partnering is a strategic priority for AstraZeneca at all stages of drug discovery and development," says Christof Angst, CNS & Pain Innovative Medicines, Vice-President, Strategy and Externalisation. "By combining our strengths with those of our partners, we are in a better position to deliver new medicines that can make a meaningful difference to patients' lives."  

About Us  

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development   and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

http://www.astrazeneca.com

Contact For Business Queries

narendra_kumar@jubilantbiosys.com , +91-9611104886



'/>"/>
SOURCE Jubilant Biosys Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant Enters Research Collaboration With AstraZeneca
2. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
5. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
9. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
Breaking Medicine Technology:
(Date:4/29/2016)... Angeles, California (PRWEB) , ... April 29, 2016 , ... ... across USA, 1Heart Caregiver Services continues its successful franchise development and expansion as it ... has an extensive managerial and administrative experience in his 32 years of working in ...
(Date:4/28/2016)... (PRWEB) , ... April 29, 2016 , ... Monthly subscription ... products on the market. They recently reviewed the ZEN BOX , the aromatherapy ... are two single essential oils (like lavender or frankincense) and one Zen Blend (like ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Association, today announced it has signed a letter of intent with Moda ... Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ProText Layouts is ... Final Cut Pro X . With ProText Layouts, video editors can create an ... match the length and scale of texts. Creating text-based videos have never been ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
Breaking Medicine News(10 mins):